Aarti Drugs Ltd. (AARTIDRUGS) fundamentals
Aarti Drugs Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AARTIDRUGS (ISIN INE767A01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Aarti Drugs Ltd. does
Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
Valuation and market data
| Last close | ₹428.30 |
|---|---|
| Market capitalisation | ₹3,909 crore |
| Enterprise value | ₹4,270 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.85 |
| Price to sales (TTM) | 1.46 |
| Book value per share | ₹150.05 |
| Dividend yield | 46.70% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Sep 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,263 crore | ₹181 crore | ₹169 crore | 0.00 |
| Mar 2025 | ₹2,187 crore | ₹199 crore | ₹157 crore | 17.24 |
| Mar 2024 | ₹2,271 crore | ₹192 crore | ₹142 crore | 15.43 |
| Mar 2023 | ₹2,500 crore | ₹205 crore | ₹153 crore | 16.50 |
| Mar 2022 | ₹2,256 crore | ₹256 crore | ₹195 crore | 21.04 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 54.4% |
|---|---|
| Foreign institutions (FII) | 1.5% |
| Mutual funds | 10.1% |
| Other domestic institutions | 0.2% |
| Retail and others | 33.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.